Lauren Goodman, a registered nurse at Juliana Clinics in Beverly Hills, says she’s had people traveling from around the US to ...

CES used to be all about consumer electronics, TVs, smartphones, tablets, PCs, and – over the last few years – automobiles.

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead toward regulatory filings for the novel HIV regimen. In Gilead's ...

Gilead Sciences Inc. (NASDAQ: GILD) on Monday shared topline results from the Phase 3 ARTISTRY-2 trial. The trial evaluated the treatment responses of adults with HIV ...

ARTISTRY-1 trial showed BIC/LEN is effective in maintaining viral suppression in HIV patients previously on complex ART regimens. BIC/LEN offers a single-tablet alternative for patients with drug-drug ...

Gilead Sciences (GILD) announced on Thursday that its Phase 3 ARTISTRY-1 trial, which tested its new single-tablet regimen of bictegravir and lenacapavir in adults with HIV, reached the primary ...

Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial. The open-label trial evaluated the treatment responses of HIV patients who are virologically ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment Biktarvy and its new long-acting pre-exposure prophylaxis (PrEP) medicine ...

– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – Gilead Sciences, Inc. (NASDAQ: GILD) today announced positive topline results from the Phase 3 ARTISTRY-1 ...

Intuitive Machines, provider of space technology and infrastructure services, has agreed to acquire Lanteris Space Systems, formerly Maxar Space Systems, from Advent International for $800 million.